Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed a 6-K disclosing changes to CEO Dr. David Stamler's remuneration package, effective October | Oct 21, 2026 |
| GTBP | EFFECT | bearish | 6/10 | GT Biopharma's S-1 registration (File No. 333-299408) became effective on October 20, 2026, covering up to 9,723,057 sha | Oct 21, 2026 |
| DRMA | EFFECT | bearish | 6/10 | Dermata Therapeutics' S-3 shelf registration (File No. 333-299391) was declared effective on October 20, 2026, enabling | Oct 21, 2026 |
| ORKA | CLUSTER | neutral | 3/10 | Two insiders at Oruka Therapeutics sold a total of $534K in open-market sales within a week. The CMO exercised and sold | Oct 20, 2026 |
| ADIL | 10-Q/A | bearish | 7/10 | Adial Pharmaceuticals filed Amendment No. 1 to its Form 10-Q for the quarter ended June 30, 2026, primarily to respond t | Oct 20, 2026 |
| PDSB | 3 | neutral | 2/10 | Bruce Wendel filed a Form 3 initial statement of beneficial ownership with PDS Biotechnology Corp, indicating he has bec | Oct 20, 2026 |
| MRK | PTAB-TRIAL | neutral | 3/10 | The PTAB granted institution of inter partes review in IPR2026-00374, allowing Merck (as petitioner Merck Sharp & Dohme | Oct 20, 2026 |
| PDSB | 8-K | neutral | 4/10 | PDS Biotechnology filed an updated corporate presentation deck on October 20, 2026, highlighting clinical data for its t | Oct 20, 2026 |
| ADIL | S-3/A | bearish | 7/10 | Adial Pharmaceuticals filed Amendment No. 1 to its S-3 registration statement to register up to 25,148,970 shares of com | Oct 20, 2026 |
| TLX | 6-K | bullish | 7/10 | Telix Pharmaceuticals reported Q3 2026 group revenue of US$245 million, up 19% YoY, driven by 30% growth in Precision Me | Oct 20, 2026 |
| TLX | PRESS-RELEASE | bullish | 6/10 | Telix reported Q3 2026 group revenue of $245M (+19% YoY), with Precision Medicine revenue up 30% to $201M, and reaffirme | Oct 20, 2026 |
| MTEX | 8-K | bearish | 6/10 | Mannatech dismissed BDO USA as its independent auditor and engaged CBIZ CPAs, effective October 15, 2026. The filing not | Oct 20, 2026 |
| RARE | SC 13G | neutral | 3/10 | Madison Avenue Partners, LP and affiliated entities filed a Schedule 13G disclosing a 6.4% passive stake in Ultragenyx P | Oct 20, 2026 |
| CRSP | CLUSTER | bearish | 5/10 | Three insiders at CRISPR Therapeutics sold a total of ~$3.15M in open-market sales within a week, including the CEO ($2. | Oct 20, 2026 |
| MLYS | 3 | neutral | 2/10 | Kristine Peterson filed an initial statement of beneficial ownership (Form 3) with the SEC, reporting zero shares owned | Oct 20, 2026 |
| ASBP | 8-K/A | mixed | 7/10 | Aspire-Lakewood Holdings, Inc. (ASBP) acquired Dura Driver Control Systems (DCS) for approximately $30 million in cash o | Oct 20, 2026 |
| MLYS | 3 | neutral | 2/10 | Lonnel Coats filed an initial Statement of Beneficial Ownership (Form 3) with the SEC, reporting zero beneficial ownersh | Oct 20, 2026 |
| RNA | PRESS-RELEASE | neutral | 2/10 | Atrium Therapeutics granted inducement stock options and restricted stock units to a new non-executive employee under it | Oct 20, 2026 |
| KOD | S-3ASR | bearish | 5/10 | Kodiak Sciences filed an automatic shelf registration (S-3ASR) on October 20, 2026, registering an unlimited amount of s | Oct 20, 2026 |
| IRON | 144 | neutral | 2/10 | Atlas Venture Opportunity Fund I, L.P., a major venture investor in Disc Medicine, filed a Form 144 notice of intent to | Oct 20, 2026 |
| IRON | 144 | neutral | 2/10 | Atlas Venture Fund X, L.P., a major venture capital shareholder of Disc Medicine (IRON), filed a Form 144 notice of inte | Oct 20, 2026 |
| IRON | 144 | neutral | 2/10 | Atlas Venture Fund XII, L.P., a major venture capital shareholder of Disc Medicine (IRON), filed a Form 144 notice of in | Oct 20, 2026 |
| FULC | S-4/A | bearish | 7/10 | Fulcrum Therapeutics (FULC) filed Amendment No. 2 to its S-4 registration statement, detailing the proposed reverse merg | Oct 20, 2026 |
| LNZA | 8-K | mixed | 6/10 | LanzaTech Global completed a recapitalization and deleveraging of its subsidiary LanzaJet, including a $10M senior secur | Oct 20, 2026 |
| SRZN | 8-K | bullish | 6/10 | Surrozen closed the second and final tranche of its March 2025 private placement, raising ~$95.1M in gross proceeds foll | Oct 20, 2026 |
| SRZN | PRESS-RELEASE | mixed | 6/10 | Surrozen closed the second tranche of its March 2025 private placement, raising ~$95.1M in gross proceeds after FDA clea | Oct 20, 2026 |
| IKT | 8-K | neutral | 3/10 | Inhibikase Therapeutics announced the resignation of director Dennis Berman and the appointment of Scott Wasserman, MD, | Oct 20, 2026 |
| AXSM | INST-CLUSTER | bearish | 4/10 | Three institutional asset managers trimmed or exited AXSM positions in Q3 2026, led by Assenagon Asset Management reduci | Oct 20, 2026 |
| CDXS | INST-CLUSTER | bearish | 4/10 | Three institutional asset managers reduced or nearly exited their positions in Codexis during Q3 2026, with aggregate ne | Oct 20, 2026 |
| HALO | INST-CLUSTER | bullish | 4/10 | Five institutional asset managers accumulated $277.5M in HALO during Q3 2026, led by Congress Asset Management ($155.7M | Oct 20, 2026 |